Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and markets therapies for rare genetic disorders of obesity. Its drug development pipeline and regulatory submissions rely on animal testing as a standard component of preclinical research. The company's public filings, including its 2024 Annual Report on Form 10-K and subsequent SEC submissions, consistently cite potential delays in "preclinical laboratory tests, animal studies" as a material risk to its business. Specific product announcements, such as updates for its MC4R pathway programs, reference reproductive toxicity assessments derived from animal studies. This places Rhythm Pharmaceuticals within the broad pharmaceutical industry practice of conducting animal testing for medical analysis and regulatory compliance, as noted by external evaluators like Cruelty Free Investors.